Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Bausch & Lomb's share price for the quarter that ended in Dec. 2023 was C$22.67. Bausch & Lomb's Shares Outstanding (EOP) for the quarter that ended in Dec. 2023 was 351 Mil. Therefore, Bausch & Lomb's market cap for the quarter that ended in Dec. 2023 was C$7,955 Mil.
Bausch & Lomb's quarterly market cap
declined
from Jun. 2023 (C$9,296 Mil) to Sep. 2023 (C$8,097 Mil) and
declined
from Sep. 2023 (C$8,097 Mil) to Dec. 2023 (C$7,955 Mil).
Bausch & Lomb's annual market cap
increased
from Dec. 2021 (C$0 Mil) to Dec. 2022 (C$7,364 Mil) and
increased
from Dec. 2022 (C$7,364 Mil) to Dec. 2023 (C$7,955 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Bausch & Lomb's Enterprise Value for Today is C$12,855 Mil.
Bausch & Lomb Market Cap Historical Data
The historical data trend for Bausch & Lomb's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Bausch & Lomb's Market Cap
For the Medical Instruments & Supplies subindustry, Bausch & Lomb's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bausch & Lomb's Market Cap Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bausch & Lomb's Market Cap distribution charts can be found below:
* The bar in red indicates where Bausch & Lomb's Market Cap falls into.
Bausch & Lomb Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Bausch & Lomb's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bausch & Lomb (TSX:BLCO) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Bausch & Lomb Market Cap Related Terms
Thank you for viewing the detailed overview of Bausch & Lomb's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Bausch & Lomb is one of the largest vision care companies in the U.S. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market which B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TSX:BLCO has been successfully added to your 